Sourced from www.nhm.ac.uk
“Vaccine Against Schistosomiasis for Africa. A Phase I clinical study of the SchistoShield® anti-schistosomiasis vaccine in adults in endemic areas of sub-Saharan Africa” — “VASA” is a project comprised of multiple studies ranging from a development of a novel vaccine against Schistosomiasis to deployment of the vaccine to relieving the burden of Schistosomiasis particularly in sub-Saharan Africa. The project is funded by the European Union (EU) and holds 10 different consortium partners from all around the world under the same goal of making the Schistosomiasis-free world.
VASA project consists of 18 work packages to be completed and this includes the following studies:
- Phase I clinical trial of Smp80-GLASE candidate vaccine (SchistoShield®) in Burkina Faso and Madagascar
- Immune signatures identification
- Correlates of Efficacy for an anti- schistosomiasis Vaccine
- Develop a Controlled Human Infection model using female S.mansoni cercariae
- Estimating the economic burden of schistosomiasis in Burkina Faso and Madagascar
- Cost effectiveness analysis for Smp80-GLASE vaccine introduction in Sub-Saharan Africa
- Sero-epidemiology study in Burkina Faso and Madagascar